董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Ross L. Levine | 男 | Director | 54 | 6.85万美元 | 未持股 | 2026-09-01 |
| Bert van Meurs | 男 | Director | 65 | 6.85万美元 | 0.60 | 2026-09-01 |
| Eva Pisa | 女 | Director | 72 | 7.55万美元 | 0.92 | 2026-09-01 |
| Eva van Pelt | 女 | Director | 61 | 7.25万美元 | 0.60 | 2026-09-01 |
| Toralf Haag | 男 | Director | 60 | 8.25万美元 | 1.78 | 2026-09-01 |
| Elizabeth E. Tallett | 女 | Director | 77 | 9.45万美元 | 6.28 | 2026-09-01 |
| Metin Colpan | 男 | Director | 71 | 8.65万美元 | 18.09 | 2026-09-01 |
| Stephen H. Rusckowski | 男 | Director | 69 | 13.28万美元 | 0.60 | 2026-09-01 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Jonathan M. Pratt | 男 | Chief Executive Officer | 56 | 未披露 | 未持股 | 2026-09-01 |
| Roland Sackers | 男 | Chief Financial Officer | 57 | 120.56万美元 | 40.68 | 2026-09-01 |
董事简历
中英对照 | 中文 | 英文- Ross L. Levine
-
Ross L. Levine于2016年加入监事会及其科学技术委员会。2021年，他成为QIAGEN科学顾问委员会主席。作为一名专注于研究和治疗血液和骨髓癌的内科科学家，莱文博士是白血病研究领域的劳伦斯·约瑟夫·迪内恩（Laurence Joseph Dineen）主席、分子癌症医学主任和纪念斯隆·凯特琳癌症中心的主治医师，以及病态康奈尔医学的医学教授。获得内科和血液肿瘤学Board认证的Levine博士获得了哈佛学院的学士学位和约翰霍普金斯大学医学院的医学博士学位。
Ross L. Levine joined the Supervisory Board and its Science & Technology Committee in 2016. In 2021, he became Chair of QIAGEN's Scientific Advisory Board. A physician scientist focused on researching and treating blood and bone marrow cancers, Dr. Levine is the Laurence Joseph Dineen Chair in Leukemia Research, the Chief of Molecular Cancer Medicine and an Attending Physician at Memorial Sloan Kettering Cancer Center, and Professor of Medicine at ill Cornell Medicine. Board certified in internal medicine and hematology oncology, Dr. Levine received a bachelor's degree from Harvard College and his M.D. from The Johns Hopkins University School of Medicine. - Ross L. Levine于2016年加入监事会及其科学技术委员会。2021年，他成为QIAGEN科学顾问委员会主席。作为一名专注于研究和治疗血液和骨髓癌的内科科学家，莱文博士是白血病研究领域的劳伦斯·约瑟夫·迪内恩（Laurence Joseph Dineen）主席、分子癌症医学主任和纪念斯隆·凯特琳癌症中心的主治医师，以及病态康奈尔医学的医学教授。获得内科和血液肿瘤学Board认证的Levine博士获得了哈佛学院的学士学位和约翰霍普金斯大学医学院的医学博士学位。
- Ross L. Levine joined the Supervisory Board and its Science & Technology Committee in 2016. In 2021, he became Chair of QIAGEN's Scientific Advisory Board. A physician scientist focused on researching and treating blood and bone marrow cancers, Dr. Levine is the Laurence Joseph Dineen Chair in Leukemia Research, the Chief of Molecular Cancer Medicine and an Attending Physician at Memorial Sloan Kettering Cancer Center, and Professor of Medicine at ill Cornell Medicine. Board certified in internal medicine and hematology oncology, Dr. Levine received a bachelor's degree from Harvard College and his M.D. from The Johns Hopkins University School of Medicine.
- Bert van Meurs
-
Bert van Meurs于2024年4月加入监事会和提名与治理委员会。他是荷兰皇家飞利浦公司（Royal Philips N.V.）执行委员会的成员，在该公司担任执行副总裁兼图像引导疗法首席BINSL负责人，同时还担任负责诊断和治疗的精准诊断（临时）首席BINSL负责人。自985年加入飞利浦担任多个全球biness领导职位以来，他已有40多年的经验。他拥有乌得勒支大学的物理学硕士学位和埃因霍温工业大学的biness市场营销学位，均在荷兰。
Bert van Meurs joined the Supervisory Board and the Nomination & Governance Committee in April 2024. He is a member of the Executive Committee at Royal Philips N.V. of the Netherlands, where he serves as Executive Vice President and Chief Biness Leader of Image Guided Therapy, and also as Chief Biness Leader of Precision Diagnosis (ad interim) responsible for Diagnosis and Treatment. He has more than 40 years of experience since joining Philips in 1985 in vario global biness leadership positions. He has a master's degree in physics from the University of Utrecht and a degree in biness marketing from the Technical University of Eindhoven, both in the Netherlands. - Bert van Meurs于2024年4月加入监事会和提名与治理委员会。他是荷兰皇家飞利浦公司（Royal Philips N.V.）执行委员会的成员，在该公司担任执行副总裁兼图像引导疗法首席BINSL负责人，同时还担任负责诊断和治疗的精准诊断（临时）首席BINSL负责人。自985年加入飞利浦担任多个全球biness领导职位以来，他已有40多年的经验。他拥有乌得勒支大学的物理学硕士学位和埃因霍温工业大学的biness市场营销学位，均在荷兰。
- Bert van Meurs joined the Supervisory Board and the Nomination & Governance Committee in April 2024. He is a member of the Executive Committee at Royal Philips N.V. of the Netherlands, where he serves as Executive Vice President and Chief Biness Leader of Image Guided Therapy, and also as Chief Biness Leader of Precision Diagnosis (ad interim) responsible for Diagnosis and Treatment. He has more than 40 years of experience since joining Philips in 1985 in vario global biness leadership positions. He has a master's degree in physics from the University of Utrecht and a degree in biness marketing from the Technical University of Eindhoven, both in the Netherlands.
- Eva Pisa
-
Eva Pisa于2022年加入监事会和薪酬与人力资源委员会。她通过旗下公司piMed Consulting担任多家生命科学和诊断公司的顾问，她曾于2007年至2020年在罗氏诊断国际公司担任高级领导职务，最近担任罗氏集中式和POC解决方案公司的高级副总裁。在加入罗氏之前，她曾于2001年至2007年担任SANTEC Molecular Diagnostics AB的首席执行官，该公司是一家SDIS初创公司。Pisa博士拥有卡罗林斯卡学院的博士学位和赫瑞瓦特大学的MBA学位。
Eva Pisa joined the Supervisory Board and the Compensation & Human Resources Committee in 2022. She is an adviser to several Life Sciences and diagnostic companies through her company piMed Consulting, and she previoly held senior leadership positions at Roche Diagnostics International from 2007 to 2020, most recently as Senior Vice President at Roche Centralized and POC Solutions. Prior to joining Roche, she was Chief Executive Officer of Sangtec Molecular Diagnostics AB, a Sdish start up, from 2001 to 2007. Dr. Pisa holds a Ph.D. from the Karolinska Institutet and an MBA from Heriot Watt University. - Eva Pisa于2022年加入监事会和薪酬与人力资源委员会。她通过旗下公司piMed Consulting担任多家生命科学和诊断公司的顾问，她曾于2007年至2020年在罗氏诊断国际公司担任高级领导职务，最近担任罗氏集中式和POC解决方案公司的高级副总裁。在加入罗氏之前，她曾于2001年至2007年担任SANTEC Molecular Diagnostics AB的首席执行官，该公司是一家SDIS初创公司。Pisa博士拥有卡罗林斯卡学院的博士学位和赫瑞瓦特大学的MBA学位。
- Eva Pisa joined the Supervisory Board and the Compensation & Human Resources Committee in 2022. She is an adviser to several Life Sciences and diagnostic companies through her company piMed Consulting, and she previoly held senior leadership positions at Roche Diagnostics International from 2007 to 2020, most recently as Senior Vice President at Roche Centralized and POC Solutions. Prior to joining Roche, she was Chief Executive Officer of Sangtec Molecular Diagnostics AB, a Sdish start up, from 2001 to 2007. Dr. Pisa holds a Ph.D. from the Karolinska Institutet and an MBA from Heriot Watt University.
- Eva van Pelt
-
Eva van Pelt于2024年3月加入监事会和审计委员会。她最近担任Eppendorf Group的联合首席执行官和管理委员会成员，Eppendorf Group是一家私人控股的德国生命科学公司。在Eppendorf任职之前，她曾在西门子、埃森哲、日立数据系统和徕卡微系统担任过越来越多的国际管理职位。她还担任德国医疗保健上市公司Paul Hartmann AG的监事会成员，以及德国荷兰商会会长。她获得了慕尼黑Ludwig Maximilians Universit t的Diplom Kauffrau学位。
Eva van Pelt joined the Supervisory Board and the Audit Committee in March 2024. She most recently served as Co CEO and member of the Management Board of Eppendorf Group, a privately held German Life Sciences company. Prior to her time at Eppendorf, she held vario international management positions of increasing responsibility with Siemens, Accenture, Hitachi Data Systems and Leica Microsystems. She also serves as a member of the Supervisory Board of Paul Hartmann AG, a publicly listed German healthcare company, and as President of the German Dutch Chamber of Commerce. She earned a Diplom Kauffrau degree from the Ludwig Maximilians Universitt in Munich. - Eva van Pelt于2024年3月加入监事会和审计委员会。她最近担任Eppendorf Group的联合首席执行官和管理委员会成员，Eppendorf Group是一家私人控股的德国生命科学公司。在Eppendorf任职之前，她曾在西门子、埃森哲、日立数据系统和徕卡微系统担任过越来越多的国际管理职位。她还担任德国医疗保健上市公司Paul Hartmann AG的监事会成员，以及德国荷兰商会会长。她获得了慕尼黑Ludwig Maximilians Universit t的Diplom Kauffrau学位。
- Eva van Pelt joined the Supervisory Board and the Audit Committee in March 2024. She most recently served as Co CEO and member of the Management Board of Eppendorf Group, a privately held German Life Sciences company. Prior to her time at Eppendorf, she held vario international management positions of increasing responsibility with Siemens, Accenture, Hitachi Data Systems and Leica Microsystems. She also serves as a member of the Supervisory Board of Paul Hartmann AG, a publicly listed German healthcare company, and as President of the German Dutch Chamber of Commerce. She earned a Diplom Kauffrau degree from the Ludwig Maximilians Universitt in Munich.
- Toralf Haag
-
Toralf Haag于2021年加入监事会和审计委员会，并担任审计委员会主席。自2024年9月起，哈格博士担任德国上市公司Aurubis AG的首席执行官兼执行董事会主席。2025年5月，Haag博士加入了比利时上市公司NV Bekaert SA的董事会。Previoly，Dr. Haag was Chief Executive and the Corporate Board of Management of Voith GmbH & Co. KGaA，a private held German technology company。在2016年加入福伊特担任首席财务官之前，Haag博士曾担任Lonza Group AG的首席财务官和执行委员会成员超过11年。Haag博士在奥格斯堡大学获得BINIS管理学位，在基尔大学获得博士学位。
Toralf Haag joined the Supervisory Board and Audit Committee in 2021 and is Chair of the Audit Committee. Since September 2024, Dr. Haag is Chief Executive Officer and Chairman of the Executive Board of Aurubis AG, a publicly listed German company. In May 2025, Dr. Haag joined the Board of Directors of NV Bekaert SA, a publicly listed Belgian company. Previoly, Dr. Haag was Chief Executive Officer and Chairman of the Corporate Board of Management of Voith GmbH & Co. KGaA, a privately held German technology company. Before joining Voith as Chief Financial Officer in 2016, Dr. Haag served for more than 11 years as Chief Financial Officer and member of the Executive Committee of Lonza Group AG. Dr. Haag earned a degree in biness administration from the University of Augsburg and a Ph.D. from the University of Kiel. - Toralf Haag于2021年加入监事会和审计委员会，并担任审计委员会主席。自2024年9月起，哈格博士担任德国上市公司Aurubis AG的首席执行官兼执行董事会主席。2025年5月，Haag博士加入了比利时上市公司NV Bekaert SA的董事会。Previoly，Dr. Haag was Chief Executive and the Corporate Board of Management of Voith GmbH & Co. KGaA，a private held German technology company。在2016年加入福伊特担任首席财务官之前，Haag博士曾担任Lonza Group AG的首席财务官和执行委员会成员超过11年。Haag博士在奥格斯堡大学获得BINIS管理学位，在基尔大学获得博士学位。
- Toralf Haag joined the Supervisory Board and Audit Committee in 2021 and is Chair of the Audit Committee. Since September 2024, Dr. Haag is Chief Executive Officer and Chairman of the Executive Board of Aurubis AG, a publicly listed German company. In May 2025, Dr. Haag joined the Board of Directors of NV Bekaert SA, a publicly listed Belgian company. Previoly, Dr. Haag was Chief Executive Officer and Chairman of the Corporate Board of Management of Voith GmbH & Co. KGaA, a privately held German technology company. Before joining Voith as Chief Financial Officer in 2016, Dr. Haag served for more than 11 years as Chief Financial Officer and member of the Executive Committee of Lonza Group AG. Dr. Haag earned a degree in biness administration from the University of Augsburg and a Ph.D. from the University of Kiel.
- Elizabeth E. Tallett
-
Elizabeth E. Tallett，2011年加入公司监事会，审计委员会和薪酬委员会。2002年她担任一家早期到中期阶段的制药，生物技术和医疗设备公司的管理公司，狩猎合伙有限责任公司的出资人。她的高级管理经验，包括transcell技术有限公司的总裁兼首席执行官，Centocor药品公司的总裁，Parke-Davis执行委员会的成员，华纳公司全球战略规划的总监。她毕业于英格兰诺丁汉大学并获得数学和经济学双学士学位的荣誉。她是Principal金融集团股份有限公司，WellPoint股份有限公司和Meredith股份有限公司董事会的成员。她目前是Principal的首席董事。在过去的五年里，她还是Varian股份有限公司，Immunicon股份有限公司，Varian半导体设备股份有限公司， Coventry医疗保健股份有限公司和美国IntegraMed股份有限公司的董事。她是新泽西生物技术委员会的创始成员，是宾夕法尼亚Solebury学校的受托人。
Elizabeth E. Tallett joined the Supervisory Board and its Audit Committee and Compensation & Human Resources Committee in 2011. In 2016, she joined the Nomination & Governance Committee. From 2002 to 2015, she was a Principal of Hunter Partners, LLC, a management company for pharmaceutical, biotechnology and medical device companies, and continues to consult with early stage healthcare companies. She previoly served as President and Chief Executive Officer of Transcell Technologies Inc.; President of Centocor Pharmaceuticals; Executive Committee member of the Parke Davis; and Director of Worldwide Strategic Planning for Warner Lambert Company. Ms. Tallett is a member of the Board of Directors of Moderna, Inc., and previoly served as Chair of the Board of Directors of Elevance Health. She was a founding board member of the Biotechnology Council of New Jersey. She earned bachelor's degrees in mathematics and economics from the University of Nottingham. - Elizabeth E. Tallett，2011年加入公司监事会，审计委员会和薪酬委员会。2002年她担任一家早期到中期阶段的制药，生物技术和医疗设备公司的管理公司，狩猎合伙有限责任公司的出资人。她的高级管理经验，包括transcell技术有限公司的总裁兼首席执行官，Centocor药品公司的总裁，Parke-Davis执行委员会的成员，华纳公司全球战略规划的总监。她毕业于英格兰诺丁汉大学并获得数学和经济学双学士学位的荣誉。她是Principal金融集团股份有限公司，WellPoint股份有限公司和Meredith股份有限公司董事会的成员。她目前是Principal的首席董事。在过去的五年里，她还是Varian股份有限公司，Immunicon股份有限公司，Varian半导体设备股份有限公司， Coventry医疗保健股份有限公司和美国IntegraMed股份有限公司的董事。她是新泽西生物技术委员会的创始成员，是宾夕法尼亚Solebury学校的受托人。
- Elizabeth E. Tallett joined the Supervisory Board and its Audit Committee and Compensation & Human Resources Committee in 2011. In 2016, she joined the Nomination & Governance Committee. From 2002 to 2015, she was a Principal of Hunter Partners, LLC, a management company for pharmaceutical, biotechnology and medical device companies, and continues to consult with early stage healthcare companies. She previoly served as President and Chief Executive Officer of Transcell Technologies Inc.; President of Centocor Pharmaceuticals; Executive Committee member of the Parke Davis; and Director of Worldwide Strategic Planning for Warner Lambert Company. Ms. Tallett is a member of the Board of Directors of Moderna, Inc., and previoly served as Chair of the Board of Directors of Elevance Health. She was a founding board member of the Biotechnology Council of New Jersey. She earned bachelor's degrees in mathematics and economics from the University of Nottingham.
- Metin Colpan
-
Metin Colpan，他是公司的共同创始人，曾担任首席执行官和董事总经理（从1985年到2003年）。他一直担任监事会的成员（2004年以来）。他于1993年获得the Darmstadt Institute of Technology的有机化学和化学工程的博士学位和硕士学位。创建QIAGEN公司之前，他曾担任the Institute for Biophysics at the University of Dusseldorf的助理研究者。他拥有丰富的经验，涉及分离技术、特别是核酸的分离和纯化，并提出许多该领域的专利。他目前担任Qalovis Farmer Automatic Energy GmbH、Laer， Germany and EM Brake Systems AG、 Schloss-Holte的监事会成员。他此前曾担任Ingenium Pharmaceuticals AG、 GenPat77 Pharmacogenetics AG、GPC Biotech AG、 Morphosys AG（均位于德国慕尼黑）的监事会成员。
Metin Colpan is a co founder of QIAGEN and was the Chief Executive Officer and a Managing Director from 1985 to 2003. Dr. Colpan has been a member of the Supervisory Board since 2004 and has been a member of the Nomination & Governance Committee since 2015. Prior to co founding QIAGEN, Dr. Colpan was an Assistant Investigator at the Institute for Biophysics at the University of Düsseldorf. He has extensive experience in sample technologies, in particular the separation and purification of nucleic acids, and has many patents in the field. Dr. Colpan obtained his doctorate and master's degree from the Darmstadt Institute of Technology. - Metin Colpan，他是公司的共同创始人，曾担任首席执行官和董事总经理（从1985年到2003年）。他一直担任监事会的成员（2004年以来）。他于1993年获得the Darmstadt Institute of Technology的有机化学和化学工程的博士学位和硕士学位。创建QIAGEN公司之前，他曾担任the Institute for Biophysics at the University of Dusseldorf的助理研究者。他拥有丰富的经验，涉及分离技术、特别是核酸的分离和纯化，并提出许多该领域的专利。他目前担任Qalovis Farmer Automatic Energy GmbH、Laer， Germany and EM Brake Systems AG、 Schloss-Holte的监事会成员。他此前曾担任Ingenium Pharmaceuticals AG、 GenPat77 Pharmacogenetics AG、GPC Biotech AG、 Morphosys AG（均位于德国慕尼黑）的监事会成员。
- Metin Colpan is a co founder of QIAGEN and was the Chief Executive Officer and a Managing Director from 1985 to 2003. Dr. Colpan has been a member of the Supervisory Board since 2004 and has been a member of the Nomination & Governance Committee since 2015. Prior to co founding QIAGEN, Dr. Colpan was an Assistant Investigator at the Institute for Biophysics at the University of Düsseldorf. He has extensive experience in sample technologies, in particular the separation and purification of nucleic acids, and has many patents in the field. Dr. Colpan obtained his doctorate and master's degree from the Darmstadt Institute of Technology.
- Stephen H. Rusckowski
-
Stephen H. Rusckowski，总裁兼首席执行官。在他2012年5月加入本公司之前，自2006年10月以来他担任皇家飞利浦电子最大的单位，飞利浦医疗的首席执行官，和皇家飞利浦电子及其执行委员会，管理委员会的成员。在此之前，他在皇家飞利浦电子公司的成像系统担任首席执行官。在2001年加入飞利浦之前，他在休利特帕卡德/安捷伦科技医疗担任过很多管理工作。他自2012N年5月起担任公司的董事。他拥有伍斯特理工学院机械工程学士学位和麻省理工学院斯隆管理学院管理科学硕士学位。
Stephen H. Rusckowski is the former Chief Executive Officer and President from 2012 until 2022 of Quest Diagnostics, Inc. (Quest), a diagnostic services company. He also served as Chair of the Board of Quest from January 2017 through March 2023. Prior to joining Quest, he served as the Chief Executive Officer of Philips Healthcare, and a member of the Board of Management of Royal Philips Electronics. Mr. Rusckowski currently serves on the supervisory board of Qiagen N.V. During the last five years, he previously served as director of Baxter International Inc. and Tenet Healthcare Corporation. - Stephen H. Rusckowski，总裁兼首席执行官。在他2012年5月加入本公司之前，自2006年10月以来他担任皇家飞利浦电子最大的单位，飞利浦医疗的首席执行官，和皇家飞利浦电子及其执行委员会，管理委员会的成员。在此之前，他在皇家飞利浦电子公司的成像系统担任首席执行官。在2001年加入飞利浦之前，他在休利特帕卡德/安捷伦科技医疗担任过很多管理工作。他自2012N年5月起担任公司的董事。他拥有伍斯特理工学院机械工程学士学位和麻省理工学院斯隆管理学院管理科学硕士学位。
- Stephen H. Rusckowski is the former Chief Executive Officer and President from 2012 until 2022 of Quest Diagnostics, Inc. (Quest), a diagnostic services company. He also served as Chair of the Board of Quest from January 2017 through March 2023. Prior to joining Quest, he served as the Chief Executive Officer of Philips Healthcare, and a member of the Board of Management of Royal Philips Electronics. Mr. Rusckowski currently serves on the supervisory board of Qiagen N.V. During the last five years, he previously served as director of Baxter International Inc. and Tenet Healthcare Corporation.
高管简历
中英对照 | 中文 | 英文- Jonathan M. Pratt
Jonathan M. Pratt于2019年8月被任命为TA Instruments高级副总裁兼总裁。在加入沃特世公司之前，普拉特先生曾是贝克曼库尔特生命科学公司的总裁。 此外，他还在颇尔公司（Pall Corporation）担任高级职位，在那里他担任了食品，饮料，实验室和ForteBio业务的总裁。
Jonathan M. Pratt,was appointed Senior Vice President, Waters Division, on May 1, 2021. Previously, he served as Senior Vice President and President, TA Instruments from August 2019 to April 30, 2021. Prior to joining Waters Corporation, Mr. Pratt was President of Beckman Coulter Life Sciences from January 2017 to April 2019. Additionally, he held senior positions at Pall Corporation from 2001 to 2017, where he was Vice President and General Manager from October 2015 to December 2016 following Pall Corporation's acquisition by Danaher Corporation and, prior to that, President of its Food & Beverage, Laboratory and ForteBio businesses from April 2011 to October 2015. Since August 2020, Mr. Pratt has served on the Board of SPX FLOW, Inc. (NYSE:FLOW) as an independent director and a member of the Audit, Compensation and Nominating & Governance Committees. He holds a Bachelor of Science in chemistry from the University of Reading in the United Kingdom and an MBA from New York University Stern School of Business.- Jonathan M. Pratt于2019年8月被任命为TA Instruments高级副总裁兼总裁。在加入沃特世公司之前，普拉特先生曾是贝克曼库尔特生命科学公司的总裁。 此外，他还在颇尔公司（Pall Corporation）担任高级职位，在那里他担任了食品，饮料，实验室和ForteBio业务的总裁。
- Jonathan M. Pratt,was appointed Senior Vice President, Waters Division, on May 1, 2021. Previously, he served as Senior Vice President and President, TA Instruments from August 2019 to April 30, 2021. Prior to joining Waters Corporation, Mr. Pratt was President of Beckman Coulter Life Sciences from January 2017 to April 2019. Additionally, he held senior positions at Pall Corporation from 2001 to 2017, where he was Vice President and General Manager from October 2015 to December 2016 following Pall Corporation's acquisition by Danaher Corporation and, prior to that, President of its Food & Beverage, Laboratory and ForteBio businesses from April 2011 to October 2015. Since August 2020, Mr. Pratt has served on the Board of SPX FLOW, Inc. (NYSE:FLOW) as an independent director and a member of the Audit, Compensation and Nominating & Governance Committees. He holds a Bachelor of Science in chemistry from the University of Reading in the United Kingdom and an MBA from New York University Stern School of Business.
- Roland Sackers
Roland Sackers，他于1999年作为财务副总裁加入公司，并一直担任首席财务官（2004年以来）。他于2006年成为管理委员会的成员。从1995年到1999年，他担任Arthur Andersen、 Wirtschaftsprüfungsgesellschaft、 Steuerberatungsgesellschaft的审计员。他获得the Westfalische Wilhelms-Universitat Münster（位于德国）的交易员硕士学位（研究企业管理之后）。直到2006年，他担任IBS公司的监事会和审计委员会的成员。他曾是Operon Biotechnologies公司的董事会成员（直到2007年12月）。他是the industry association BIO Deutschland的董事会成员。他也是Immunodiagnostic Systems Holding（IDS，免疫学检测研究和诊断应用程序的主要制造商，在英国上市）的审计委员会主席和非执行的董事。他也担任QIAGEN Marseille公司（QIAGEN公司于2011年收购的握有过半股权的附属机构）的董事会成员和审计委员会主管。
Roland Sackers has served as a Member of the Supervisory Board since June 2019 and is chairman of the audit committee. Since 2004, Mr. Sackers has been CFO of QIAGEN N.V. In 2006, Mr. Sackers became a member of the Managing Board. Between 1995 and 1999, he served as an auditor with Arthur Andersen Wirtschaftsprüfungsgesellschaft Steuerberatungsgesellschaft. He is a former member of the supervisory board and audit committee of IBS AG and a former member of the board of directors of Operon Biotechnologies, Inc. Mr. Sackers is as a board member of the industry association BIO Deutschland, previously a non executive director and chair of the audit committee from 2011 to 2018 of Immunodiagnostic Systems Holding PLC (IDS), a leading producer of immunological tests for research and diagnostic applications publicly listed in the UK. Mr. Sackers earned his Diplom Kaufmann from University of Münster, Germany.- Roland Sackers，他于1999年作为财务副总裁加入公司，并一直担任首席财务官（2004年以来）。他于2006年成为管理委员会的成员。从1995年到1999年，他担任Arthur Andersen、 Wirtschaftsprüfungsgesellschaft、 Steuerberatungsgesellschaft的审计员。他获得the Westfalische Wilhelms-Universitat Münster（位于德国）的交易员硕士学位（研究企业管理之后）。直到2006年，他担任IBS公司的监事会和审计委员会的成员。他曾是Operon Biotechnologies公司的董事会成员（直到2007年12月）。他是the industry association BIO Deutschland的董事会成员。他也是Immunodiagnostic Systems Holding（IDS，免疫学检测研究和诊断应用程序的主要制造商，在英国上市）的审计委员会主席和非执行的董事。他也担任QIAGEN Marseille公司（QIAGEN公司于2011年收购的握有过半股权的附属机构）的董事会成员和审计委员会主管。
- Roland Sackers has served as a Member of the Supervisory Board since June 2019 and is chairman of the audit committee. Since 2004, Mr. Sackers has been CFO of QIAGEN N.V. In 2006, Mr. Sackers became a member of the Managing Board. Between 1995 and 1999, he served as an auditor with Arthur Andersen Wirtschaftsprüfungsgesellschaft Steuerberatungsgesellschaft. He is a former member of the supervisory board and audit committee of IBS AG and a former member of the board of directors of Operon Biotechnologies, Inc. Mr. Sackers is as a board member of the industry association BIO Deutschland, previously a non executive director and chair of the audit committee from 2011 to 2018 of Immunodiagnostic Systems Holding PLC (IDS), a leading producer of immunological tests for research and diagnostic applications publicly listed in the UK. Mr. Sackers earned his Diplom Kaufmann from University of Münster, Germany.